Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Radioimmunodetection of cancer with monoclonal antibodies: current status, problems, and future directions

Journal Article · · CRC Crit. Rev. Oncol./Hematol.; (United States)
Early studies of immunoscintography with affinity-purified /sup 131/I-labeled polyclonal antibodies reactive against oncofetal antigens such as carcinoembryonic antigen (CEA) were moderately successful in detecting metastatic colorectal carcinoma. However, because of low tumor to background ratios of isotope, background subtraction techniques using /sup 99/Tc-labeled albumin were required to visualize small lesions. Antisera were often of low titer and lacked specificity. These problems could be overcome for the most part following the development of highly specific monoclonal antibodies (MoAb) against a variety of tumor-associated antigens. A number of clinical trials using /sup 131/I- or /sup 111/In-labeled MoAb to image tumors have demonstrated successful localization without the use of subtraction techniques. Variables limiting the usefulness of murine MoAb for diagnosis have included increased localization in liver and spleen, tumor vascularity and heterogeneity of antigen expression, and development of human antimurine globulins. Methods to overcome some of these problems are discussed. Radiolabeled MoAb appear useful as an adjunct to conventional diagnostic techniques both as a means to predict which antibodies might be useful for treatment and, in select patients, as a basis for treatment decisions. 163 references.
Research Organization:
M.D. Anderson Hospital and Tumor Institute, Houston, TX (USA)
OSTI ID:
6543569
Journal Information:
CRC Crit. Rev. Oncol./Hematol.; (United States), Journal Name: CRC Crit. Rev. Oncol./Hematol.; (United States) Vol. 8:3; ISSN CCRHE
Country of Publication:
United States
Language:
English